Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters.
Serotonin (5-hydroxytryptamine, 5-HT) has long been implicated in regulation of mood. Medications that block the neuronal 5-HT transporter (SERT) are used as major pharmacological treatment for mood disorders. Conversely, stimuli that enhance SERT activity might be predicted to diminish synaptic 5-HT availability and increase the risk for 5-HT-related CNS disorders. We have shown that the inflammatory cytokines enhance brain SERT activity in cultured serotonergic cells and nerve terminal preparations in vitro. In this study, we establish that intraperitoneal injection of the cytokine-inducer lipopolysaccharide (LPS) stimulates brain SERT activity, acting at doses below those required to induce overt motor suppression. SERT stimulation by LPS is paralleled by increased immobility in both the tail suspension test (TST) and the forced swim test (FST); antidepressant-sensitive alterations are thought to model aspects of behavioral despair. Both the stimulation of SERT activity and induced immobility are absent when LPS is administered to interleukin-1 receptor (IL-1R)-deficient mice and in the presence of SB203580, an inhibitor of IL-1R-stimulated p38 MAPK. Moreover, the ability of LPS to enhance immobility in TST is lost in SERT knockout mice. These findings reveal an ability of peripheral inflammatory stimuli to enhance brain SERT activity through IL-1R and p38 MAPK pathways in vivo and identify a requirement for SERT expression in immune-system-modulated despair behaviors. Our studies identify IL-1R- and p38 MAPK-dependent regulation of SERT as one of the mechanisms by which environmentally driven immune system activation can trigger despair-like behavior in an animal model, encouraging future analysis of the pathway for risk factors in neuropsychiatric disorders.
Zhu
Chong-Bin
CB
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Lindler
Kathryn M
KM
Owens
Anthony W
AW
Daws
Lynette C
LC
Blakely
Randy D
RD
Hewlett
William A
WA
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003863:Depression / Q000139:chemically induced* / Q000517:prevention & control; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011725:Pyridines / Q000494:pharmacology; D017472:Receptors, Interleukin-1 / Q000235:genetics / Q000378:metabolism*; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism*; D013574:Synaptosomes / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D007093:Imidazoles; D008070:Lipopolysaccharides; D011725:Pyridines; D017472:Receptors, Interleukin-1; D050486:Serotonin Plasma Membrane Transport Proteins; C493231:Slc6a4 protein, mouse; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580
Psychopharmacology (Berl). 2001 Feb;154(1):50-60
11292006
Brain Res. 1996 Mar 4;711(1-2):163-74
8680860
Mol Psychiatry. 2003 Nov;8(11):933-6
14593431
Adv Exp Med Biol. 1999;461:283-316
10442179
Eur J Neurosci. 2008 Dec;28(12):2499-510
19087175
Nat Rev Neurosci. 2008 Jan;9(1):46-56
18073775
Biochem Biophys Res Commun. 1995 Nov 13;216(2):560-7
7488148
Adv Exp Med Biol. 1999;461:25-46
10442165
Mol Psychiatry. 2009 May;14(5):511-22
18195714
Brain Behav Immun. 2006 Nov;20(6):569-77
16554144
Brain Behav Immun. 2003 Feb;17 Suppl 1:S119-24
12615197
Gynecol Endocrinol. 1996 Jun;10(3):149-54
8862488
Curr Psychiatry Rep. 2006 Dec;8(6):452-7
17094925
Neuroendocrinology. 1992 Dec;56(6):935-8
1369606
Mol Psychiatry. 2008 Jul;13(7):717-28
17700577
Physiology (Bethesda). 2005 Aug;20:225-31
16024510
Pharmacol Biochem Behav. 1993 Dec;46(4):787-91
8309956
Psychoneuroendocrinology. 2003 Jan;28(1):19-34
12445834
Brain Res. 1995 Dec 24;705(1-2):302-6
8821761
Acta Psychiatr Scand. 1988 Aug;78(2):176-81
3223316
Acta Psychiatr Scand. 2001 Mar;103(3):226-8
11240580
CNS Neurol Disord Drug Targets. 2006 Oct;5(5):547-60
17073657
J Neuroinflammation. 2008 Mar 18;5:10
18348728
Neurosci Lett. 2009 May 29;456(1):39-43
19429130
Neurochem Int. 1998 Sep;33(3):251-4
9759920
Psychosom Med. 2009 Feb;71(2):171-86
19188531
Brain Res. 1995 Oct 16;695(2):279-82
8556346
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):751-6
18178625
Neuropsychobiology. 1996;33(4):202-9
8840344
J Neuroimmunol. 2005 Jun;163(1-2):53-72
15885308
Neuropsychopharmacology. 2001 May;24(5):531-44
11282253
Nat Rev Neurosci. 2003 Dec;4(12):1002-12
14618156
J Neurosci Res. 1995 Feb 15;40(3):407-13
7745636
J Pharmacol Exp Ther. 2001 Nov;299(2):666-77
11602680
Curr Opin Investig Drugs. 2009 Jul;10(7):664-71
19579172
Science. 2003 Jul 18;301(5631):386-9
12869766
Am J Geriatr Psychiatry. 2010 Feb;18(2):172-6
20104073
Clin Neurosci Res. 2006 Aug;6(1-2):52-68
18079991
Pharmacol Biochem Behav. 2007 Apr;86(4):651-9
17360031
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102
12551730
Neurosci Lett. 2009 Feb 13;451(1):79-82
19103261
Infect Immun. 1990 Nov;58(11):3743-50
2228245
Neurosci Biobehav Rev. 2005;29(4-5):571-625
15890404
Alcohol Clin Exp Res. 2009 Aug;33(8):1329-35
19426172
J Psychiatry Neurosci. 2009 Jan;34(1):4-20
19125209
J Affect Disord. 2001 Jan;62(1-2):57-76
11172874
Trends Immunol. 2006 Jan;27(1):24-31
16316783
Philos Trans R Soc Lond B Biol Sci. 2009 Jan 27;364(1514):163-73
18957375
Life Sci. 2001 Jan 12;68(8):873-80
11213357
Biol Psychiatry. 2010 Mar 1;67(5):446-57
20015486
Psychopharmacology (Berl). 2003 Dec;170(4):429-33
12955291
J Psychopharmacol. 2007 Jul;21(5):538-44
17446201
Neuropsychopharmacology. 2006 Oct;31(10):2121-31
16452991
Ann N Y Acad Sci. 2000;917:478-87
11268375
J Neurosci. 2005 Jan 5;25(1):29-41
15634764
Exp Gerontol. 2007 Jul;42(7):693-701
17350781
Int J Neuropsychopharmacol. 2009 Jul;12(6):737-47
19154632
J Biol Chem. 2005 Apr 22;280(16):15649-58
15728187
Physiol Behav. 2009 Aug 4;98(1-2):139-46
19414023
Ann N Y Acad Sci. 2006 Nov;1088:230-7
17192569
Neuropsychobiology. 1999 Nov;40(4):171-6
10559698
Mol Psychiatry. 2007 Nov;12(11):988-1000
17457312
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18976-81
19033200
Eur J Neurosci. 2005 Dec;22(11):2817-26
16324116
J Neurosci Res. 2003 Mar 1;71(5):701-9
12584728
Pharmacol Biochem Behav. 2005 Jul;81(3):688-93
15982728
J Neuroimmunol. 2000 Apr 3;104(1):31-6
10683512